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Immune control of viral infections is modulated by diverse T cell receptor (TCR) clonotypes engaging
peptide-MHC class I complexes on infected cells, but the relationship between TCR structure and antiviral
function is unclear. Here we apply in silico molecular modeling with in vivo mutagenesis studies to
investigate TCR-pMHC interactions from multiple CTL clonotypes specific for a well-defined HIV-1
epitope. Our molecular dynamics simulations of viral peptide-HLA-TCR complexes, based on two
independent co-crystal structure templates, reveal that effective and ineffective clonotypes bind to the
terminal portions of the peptide-MHC through similar salt bridges, but their hydrophobic side-chain
packings can be very different, which accounts for themajor part of the differences among these clonotypes.
Non-specific hydrogen bonding to viral peptide also accommodates greater epitope variants. Furthermore,
free energy perturbation calculations for point mutations on the viral peptide KK10 show excellent
agreement with in vivo mutagenesis assays, with new predictions confirmed by additional experiments.
These findings indicate a direct structural basis for heterogeneous CTL antiviral function.
C
hronic viral infections in mice and humans are modulated by cytotoxic T lymphocyte (CTL)-mediated
immune pressure, but the level of immune control is quite variable. This is particularly apparent with
HIV-1, a chronic human viral infection that undergoes rapid sequence variation under CTL-mediated
immune pressure (see details in a recent review1). Immune escape is impeded by the elicitation of a diverse T cell
response consisting of multiple specificities2,3, but these can vary significantly in antiviral efficacy4–6. Some
induced responses effectively target both wild-type (WT) virus and naturally arising mutants, impeding the
development of immune escape7–9. Others are readily detectable by tetramer staining, but exhibit little antiviral
function in vitro, and appear to exert little immune selection pressure in vivo7.
These differences among CTL clonotypes in potency and cross-reactivity of recognition of HIV-1 and its
variants7 are in line with the T cell receptor (TCR)-based modulation of effector cell subsets10 and suggest that the
fine specificity of TCRs may modulate their antiviral function7,8,11–13. Although a co-crystalized X-ray structure
has recently been reported for a single clonotype interacting with the human leukocyte antigen (HLA) B*2705-
restricted epitopeKK10 (KRWIILGLNK, Gag aa 263–272)11, the underlyingmolecularmechanism for clonotypic
differences in antiviral efficacy against this and other epitopes has not been fully understood due to the limited
availability of co-crystalized structures of the TCR-peptide-MHC complexes.
In this study, we used a combined approach employing both experimental and theoretical techniques to
address the relationship between HIV-1 peptide (KK10)-HLA-TCR complex structure and function. We took
advantage of unique reagents generated from persons with untreated HIV-1 infection: intrapatient CTL clones
with distinct TCR clonotypes, all induced in vivo against the same HLA B*2705-restricted epitope in Gag, but
differing in measures of antiviral function. Using molecular dynamics (MD) simulations coupled with functional
assays, we show that specific binding patterns among KK10-HLA (B*2705)-TCR interactions are associated with
























SCIENTIFIC REPORTS | 4 : 4087 | DOI: 10.1038/srep04087 1
Results
Antiviral function of KK10-specific clonotypes. Previously estab-
lished HLA-B*2705 KK10-specific CTL clonotypes B3, B5 and B6
derived from anHIV-1 controller (FW56) were used in these studies.
All clonotypes had considerable sequence diversity in TCR comple-
mentarity determining regions (CDRs), and differed in Vb and Va
gene usage7 (Table S1). For example, the sequence identities are only
,30% between clones B3, B5, and between clones B5, B6 (Table S2).
These clones represented both dominant and subdominant clono-
types present in vivo, but differed markedly in their ability to inhibit
virus replication in vitro7. Repeated testing using cryopreserved
samples revealed that these clonotypes maintained stable diffe-
rences in their ability to recognize CD4 T cells infected with HIV-
1, as shown in the specific lysis assays (Fig. 1A). It is clear that
clonotype B5 broadly recognized the WT and its variant viruses,
whereas B3 robustly recognized WT virus but showed little cross-
reactivity against variants. In contrast, B6 exhibited weak and narrow
recognition. The molecular or structural basis for this diversity
among different clonotypes is still largely unknown, which is the
main focus of the following large scale molecular modeling.
Structural modeling of TCR-pMHC interaction. Having defined
clonotypic difference of antiviral efficacy, we next examined struc-
tural properties of effective and ineffective clonotypes in an attempt
to relate function to structure. Computational methods have been
widely used in structural modeling of biomolecular complexes.
In particular, template-based models (homology models) have
demonstrated high accuracy in protein structure predictions, as
shown in recent CASP competitions14,15. Meanwhile, large-scale
free energy perturbation (FEP) is regarded as the most rigorous
and reliable method in predicting binding affinities, which has also
achieved high accuracy in characterizing key residues and their
mutational effects for many protein-protein and protein–ligand
bindings, as compared with experiments16–18. We thus went on to
investigate the structural features, dynamic properties, and muta-
tional effects of the ternary binding complexes of KK10-HLA
(B*2705)-TCR with computational techniques. Here we used two
independent co-crystal structures as templates (more below) to
construct homology models of the ternary binding complexes for
each FW56 TCR clonotype (see Materials and Methods section for
more details), which does not have a crystal structure yet. Consi-
dering the high sequence diversities among these TCR clonotypes, it
is also difficult, if not impossible, to experimentally determine all
KK10-HLA-TCR complex structures here. After the modeling
construction, we then performed an aggregate of microsecond MD
simulations of these complexes in explicit solvent using IBM Blue
Gene supercomputers, which allows us to study their dynamics with
atomic resolution. The sensitivity to viral peptide mutants of various
clonotypes was also quantitatively measured by calculating their
binding affinity changes with FEP (more below).
One representative model of the complex structure for the
clonotype B5 is shown in Fig. 2. The viral peptide fits well into the
binding groove formed at the interface of the HLA and the TCR.
Extensive MD simulations also indicate that these model structures
Figure 1 | Differential antiviral efficacy of B*27-KK10 specific clonotypes. (A). The ability of KK10-specific clonotypes to recognize NL4-3
wild-type and variant viruses was tested in the standard 4-h chromium release assay with virally infectedHLA-B*2705-encoding green fluorescent protein
(GFP) reporter GXR cells at an effector/target cell ratio of 151. Viable infected (GFP-positive) GXR cells were sorted by a FACS Aria cell-sorting
instrument after infection for 5 days and used as target cells. (B). The FEP simulation results for the predicted TCR-KK10 binding free energy change due
to L6M and R2T single mutations, and R2TL6M double mutation in viral peptide KK10.
www.nature.com/scientificreports
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of clonotypes B3, B5 and B6 are stable, as shown by RMSDs (Fig. S1),
indicating a reasonable construction of homology models.
Conserved binding features for functionally different clonotypes.
The simulated structures revealed a similar binding mode (binding
pocket) on TCRs for KK10-HLA over all clonotypes examined, with
more than 20 residues from both the TCR and theHLA-KK10 binary
complex involved at the binding site (Fig. 3). We first examined in-
teractions involving the N and C termini of the viral peptide KK10.
Although the sequence of the TCR a chain in the clonotype B5 is
different from that in clonotypes B3 and B6, we found three common
salt-bridges in all clonotypes at the N-terminus of KK10: Lys1 of
KK10 with Glu63 of HLA, Arg2 of KK10 with Glu45 of HLA, and
Lys1 of KK10 with Asp27/29 at CDR1a loop of the TCR. In
particular, for the effective clonotypes B3 and B5, KK10 is further
stabilized by extra hydrogen bonds between Glu45/Glu63 of HLA
and the amide group at theN-terminus of KK10 (Fig. 3A). TheGlu63
at the B pocket of HLAwas also recently recognized by genome-wide
association analysis (GWAS) as one of the key residues in the single-
nucleotide polymorphism of HIV-1 controllers and progressors19,20.
Similarly, favorable electrostatic interactions contribute to the C-
terminal stabilization of the viral peptide. A salt-bridge between
Lys10 of KK10 and Asp77 of HLA is found across all clonotypes,
while Asn9 of KK10 provides additional stability via hydrogen bonds
with polar/charged residues from the CDRb of the TCR (Fig. 3B).
Thus, conserved and well-organized salt-bridges and hydrogen
bonds play an important role in securing KK10 tightly into the
binding pocket between the HLAs and the TCRs. These common
N- and C-terminal features contribute to the overall binding affinity
between KK10-HLA and TCRs in all clonotypes examined.
Specific hydrophobic packing patterns determine the antiviral
efficacy and sensitivity to viral peptide mutants of the clono-
types. Contrary to the highly conserved interactions with the
terminal residues of KK10, the central residues are shown to have
a more diverse and sophisticated interaction with the CDR loops of
TCRs, thus endowing clonotypes B3, B5, and B6 with distinct
interactive features. The clonotype B3, effective against WT KK10,
has a well-defined hydrophobic packing between the viral peptide
and the CDR3b of the TCR (Fig. 3C), where Leu6 and Leu8 of KK10
form favorable contacts with Pro96 and Leu98 of the CDR3b,
respectively. The hydrophobic interaction is further enhanced by
the additional contacts with hydrophobic residues Ile66, Ala69,
and Val152 of the HLA. The formation of a stable hydrophobic
core, accompanied by a lower desolvation penalty, makes the B3
TCR and pMHC association more specific. Furthermore, such
hydrophobic core (or cavity) formed by nanoscale dewetting
(drying) was suggested to provide a substantial driving force for
protein complex collapse and overall stability in our previous
studies21–23. This strong and specific hydrophobic interactions in
B3 clonotype (KK10-Leu6 with B3 TCR’s Pro96, KK10-Leu8 with
B3 TCR’s Leu98; see Fig. 3) not only indicates high antiviral efficacy
of B3 to the WT virus, but also implies a potentially relatively weak
cross-reactivity against variants (i.e. more sensitive to mutants; see
more below), as was seen experimentally.
In order to further assess the sensitivity to viral peptide mutants of
clonotype B3, whichwas effective againstWTvirus but less so against
mutants, we calculated binding affinity changes due to mutations
frequently occurring in vivo (i.e., L6M, R2T and R2TL6M) in
KK10 (Fig. 1B). Overall, our in silicomutagenesis studies show excel-
lent agreement with those in vivo data. Our rigorous FEP calculations
show a dramatic weakening in the binding affinities for both R2T
(DDG 5 7.88 6 1.80 kcal/mol) and R2TL6M (DDG 5 13.17 6
0.83 kcal/mol) mutants, albeit a somewhat milder reduction in the
single L6M mutation (DDG 5 0.81 6 0.24 kcal/mol, which is equi-
valent to a ,4-fold increase of the dissociation constant Kd) (see
Table S3), consistent with the specific lysis assay data (Fig. 1A). For
more details, the structural comparison reveals that the L6M variant
introduces a relatively less hydrophobic side chain to position 6 of
KK10, which slightly weakens the well-packed hydrophobic core
formed in the WT peptide (Fig. 4A), while the R2T mutant directly
destroys the highly conserved salt-bridge between Arg2 in KK10 and
Glu45 in HLA. Moreover, the R2T mutation also indirectly loosens
another important salt-bridge between Lys1 in KK10 and Asp29 at
the CDR1a of the TCR through conformational distortion (Fig. 4B).
The even larger decrease in binding affinity for the R2TL6M double
mutant is found to be related to larger conformational distortions
and serious damage in conserved ‘‘signature salt-bridges’’ (Fig. 4C
and 4D).
The binding between the clonotype B5, which is potent against
WT virus and variants (see Fig. 1A), and the central residues of KK10
is more complicated due to combined effects of both specific side-
chain and non-specific backbone interactions (Fig. 3C). In WT
KK10, Leu6 makes hydrophobic contacts with Tyr31 in the
CDR1b and Val50 in the CDR2b of the TCR. Meanwhile, Gln98 in
the CDR3b forms three hydrogen bonds with nitrogen in the indole
ring of Trp3, and backbone carbonyl groups of Leu6 and Gly7 of
KK10, respectively. These hydrogen bonds are considered as ener-
getically favored, which could enhance the binding affinity between
TCR and KK10. We note that two of the hydrogen bonds are formed
with the backbone of KK10 (Gly7 with B5 TCR’s Gln98), indicating a
lesser sensitivity to the side-chain variations of KK10 (they only
interact with the backbone amide and carbonyl groups) (Fig. 3C),
which is different from the very specific hydrophobic interaction
patterns in B3 clonotype.
These structural observations explain why the clonotype B3 has
higher sensitivity to viral peptide mutants against HIV-1 in vivo
mutants than the clonotype B5. Our FEP study of the clonotype B5
further confirms this (Fig. 1B), in that there is no apparent binding
affinity change in themutant peptide L6M (DDG5 0.076 0.30 kcal/
mol), and slightly unfavorable changes in R2T (DDG 5 0.78 6
1.21 kcal/mol) and R2TL6M (DDG 5 0.92 6 0.95 kcal/mol)
mutants (Table S3), again in excellent agreement with the in vitro
experiment. The structural comparisons between these mutants also
reveal that the key interactions observed in theWTKK10 peptide are
well preserved with no observable binding mode change (Fig. S2),
providing a structural basis for the superior efficacy of the clonotype
B5 over the broad viral mutations.
The interaction between the least effective clonotype, B6, andWT
KK10 peptide is less complex. Only two hydrogen bonds are available
Figure 2 | Structural view of HLA B*2705-KK10-TCR 3-way binding
complex. The HLA-B*2705 is shown in green; the KK10 viral peptide is
colored in cyan; and the TCR is colored in magenta. All the structural
figures are generated with PyMol software.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 4 : 4087 | DOI: 10.1038/srep04087 3
between the CDR3b of the TCR (Arg99 and Arg102) and KK10
peptide (the backbone of Gly7, and the side chain of Asn9, see
Fig. 3C). The relatively weak antiviral efficacy, shown in the func-
tional lysis assay (Fig. 1A), is consistent with a lack of favorable
hydrophobic interaction, as compared to the clonotypes B3 and B5
(Fig. 3C; also see Fig. S3 and Note 1 in supplementary data).
Alanine substitutions further confirm the structural basis for
antiviral efficacy. These in silico data suggest specific molecular
interactions that modulate antiviral efficacy of specific clonotypes.
We next extended the FEP calculations with alanine substitutions
(R2A, L6A and R2AL6A) in KK10 peptide, to further investigate the
structural basis and intrinsic roles of these important residues in the
binding specificity and functional attributes of these clonotypes.
Overall, the alanine mutants display a similar trend in binding affi-
nity changes as those naturally occurringmutants (Table S4). For the
clonotype B3, the binding affinity is slightly reduced with the L6A
mutant (DDG 5 0.50 6 0.51 kcal/mol) as compared to the L6M
mutant (Fig. 5A). Although alanine is a smaller and less hydro-
phobic residue than the original leucine, it is observed that other
hydrophobic residues Ile66 and Ala69 in the HLA can adjust
themselves to closely pack with Ile4 of KK10 (Fig. S4A). Similar to
the R2T variant, a dramatic decrease in the binding affinity (DDG 5
8.13 6 3.55 kcal/mol) is observed in the R2Amutation, again due to
the loss of conserved signature salt-bridges at N-terminus (Fig. S4B).
For the clonotype B5, all alanine mutants result in relatively small
binding affinity losses, but slightly larger than those in vivomutants
L6M, R2T, and R2TL6M (Fig. 5A and Fig. S5), meaning that the low
sensitivity to viral peptide mutants is still largely maintained in the
alanine mutants in the clonotype B5, as found experimentally.
Similarly, the binding affinity changes of alanine mutants in the
clonotype B6 are very close to those in vivo mutants (Fig. S6, also
see Note 2 in supplementary data). These FEP predictions are then
confirmed by our experimental data from the specific lysis assay
(Fig. 5B), indicating our combined approach can quantitatively
measure even small differences in binding affinities, thus revealing
a direct relationship between peptide-HLA-TCR structure and
function.
A second co-crystal structure template further confirms our ho-
mology models. It should be noted that a new co-crystal structure
with the same HLA-KK10 but a different TCR clonotype was
recently reported11. We repeated the structural modeling process
for clonotypes B3, B5 and B6 using this new co-crystal structure as
a second template, and found the newly built homology models
shared very similar structures, with comparable binding modes for
KK10 as those from the previous template24,25 (Fig. S7). For example,
we found similar salt-bridges and polar interactions between TCR
and KK10 peptide in different clonotypes, and similar hydrophobic
interactions in B3 and B5 clonotypes. We also repeated the FEP
calculations for two representative in vivo mutants, L6M and R2T
in KK10, which again displayed very similar binding affinity changes
with the previous case for all the three clonotypes (see data in Table
S5). These findings further support our conclusion that specific
structural characteristics of epitope-specific clonotypic TCRs modu-
late TCR engagement and CTL antiviral efficacy.
Figure 3 | Structural comparison of different clonotypes bound to the KK10 peptide.The binding site and interactions at the N-terminal region (A), the
C-terminal region (B), and the middle region (C) of KK10 peptide are rendered with spheres (non-polar interactions) or sticks (polar interactions)
(green, HLA; cyan, HIV-1 KK10 peptide; magenta, TCR). The overall complexes are represented as cartoons. The representative snapshots were taken
from totally 600-ns molecular dynamic simulations.
www.nature.com/scientificreports
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Discussion
Multiple mechanisms (e.g. the induced-fit model) have been pro-
posed for the TCR and pMHC recognition and binding25–27. The
TCR-peptide-MHC ternary complex cannot be easily extrapolated
from the free peptide-MHC structure, since TCR-peptide recog-
nition is mainly determined by the highly flexible and variable
CDR loops. Using a panel of TCR clonotypes specific for the same
protective pMHC but differing in antiviral function, we show that
conserved polar interactions, including salt-bridges and hydrogen
bonds, are presented in both effective and ineffective clonotypes,
despite TCR usage of different Va and Vb genes. Meanwhile, signifi-
cantly different packing modes are observed among the clonotypes,
especially with the mostly hydrophobic central residues of the viral
peptide, which suggests a key role in antiviral efficacy as well as in
cross-reactivity.
These studies also allowed us to examine structure and function
relationships in the relative ability of different TCR clonotypes to
recognize naturally occurring variants within the targeted epitope.
CTL-mediated control in rapidly mutating viral infections results
from specific TCR-pMHC interactions that trigger antiviral efficacy
as well as non-specific interactions that provide a degree of tolerance
to the sequence variation of the viral peptide26,28,29. Our results using
functionally distinct clonotypes from an HIV-1 controller show the
impact of the interplay of both specific hydrophobic interactions and
non-specific hydrogen bonds in the TCR-viral peptide interaction. In
the case examined here, the strong antiviral efficacy of the clonotype
B5 is mainly derived from the favorable hydrophobic interactions
between the central viral peptide residues and the corresponding
hydrophobic residues in the CDR loops. Additionally, the low sens-
itivity to viral peptide mutants of the clonotype B5 is largely main-
tained by the strong non-specific hydrogen bonds (also known as
dehydrons, which are buried or partially buried hydrogen bonds30)
between the viral peptide backbone and Gln98 at the CDR3b of the
TCR. These dehydrons are energetically very favored, which enhance
the binding affinity between KK10 and TCR, resulting in a less sens-
itivity to mutations. Compared to the clonotype B5, B3’s TCR pre-
dominantly uses highly specific hydrophobic interactions for
contacts with the central residues Leu6 and Leu8 of KK10. This
may explain why the high antiviral efficacy is achieved in the clono-
type B3, but with a rather high sensitivity to viral peptide variants.
There are larger conformational distortions in the clonotype B3 upon
mutations. For example, in the R2T mutant, serious damages to the
conserved signature salt-bridge (KK10 Lys1 – TCRAsp29) were seen
(Figure S8).
These structural analyses were further validated by calculating the
binding affinity changes due to point mutations in the viral peptide
with the rigorous FEPmethod. Intrapatient analyses in subject FW56
for clonotypes B3, B5 and B6 showed a clear hierarchy between
binding affinity and antiviral efficacy and cross-reactivity. Specific
structural alterations accounting for much larger binding affinity
losses were found for the KK10 in vivo mutants for clonotype B3,
indicating a high sensitivity to viral peptide mutants, such as R2T,
L6M and R2TL6M, which was confirmed by in silico FEP calcula-
tions. Additional FEP predictions for all the corresponding alanine
substitutions were then further validated by in silico mutagenesis
studies. The excellent agreements between in silico and in vivomuta-
genesis studies indicate our current structural models and analyses
might be reasonable. In particular, our FEP calculations successfully
predicted a larger binding affinity change for L6A and R2A mutants
than those naturally occurring L6M and R2T ones in the KK10
peptide with the clonotype B5, which were confirmed by our experi-
mental assays. These findings are consistent with recent studies
showing that TCR composition and associated signaling potential
may modulate effector cell patterning10.
Figure 4 | Structural comparison of HLA B*2705-KK10-TCR complexes due to in vivo occurring mutants. The following mutations of KK10
peptide for FW56 clone B3 is shown (green, HLA; cyan, the HIV KK10 peptide; magenta, TCR): (A) L6Mmutant. (B) R2Tmutant. (C) and (D) R2TL6M
double mutant. The overall complex is represented as cartoon and the residues at the binding site are rendered with spheres (non-polar interactions) or
sticks (polar interactions).
www.nature.com/scientificreports
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We conclude that by applying rigorous binding affinity prediction
tools with in vivomutagenesis studies, we not only capture structural
and energetic details of particular substitutions, but also reveal the
underlying molecular mechanism for differences among TCR clo-
notypes in their potency and cross-reactivity. This study provides
structural and mechanistic insights into T cell-mediated antiviral
immunity in a chronic human viral infection.
Methods
Chromium release assay. HLA-B*2705-expressing green fluorescent protein (GFP)
reporter CEM-derived GXR cells (which contain a plasmid encoding GFP driven by
the long terminal repeat of HIV-1) were constructed as described31 and infected with
the NL4-3 virus or viral variants expressing one or more mutations in the gene
encoding Gag p24 KK10 peptide (KRWIILGLNK, Gag aa 263–272) by site-directed
mutagenesis32 at the specified multiplicity of infection (MOI). On day 5 after
infection, viable virally infected cells were sorted on a FACS Aria cell-sorting
instrument (BDBiosciences) and labeledwith chromium for 1 hr at 37uC.CTL clones
were then added at the indicated effector-target ratios, and a standard 4-h chromium
release assay was performed as previously described33. Percent specific lysis was
calculated as [(mean experimental cpm2mean spontaneous cpm)/(meanmaximum
cpm 2 mean spontaneous cpm)] 3 100. Spontaneous and maximum releases were
determined by incubating the labeled target cells with medium alone or 2% Triton X-
100, respectively.
Structural modeling of HLA B*2705-KK10-TCR complexes. Two independent
templates were used in our homology structure modeling for the viral peptide-HLA-
TCR complexes. For the first template, the binary structure ofHLAB*2705 andKK10
peptide (KRWIILGLNK) complex was taken directly from the co-crystallized x-ray
structure (PDB entry 2BSS)34. The structures of three different TCR clonotypes,
TCRBV4-3 (B3), TRBV6-5 (B5), and TRBV20-1 (B6) of a controller FW56, were built
from their closest homologs, with MODELLER software package35,36, based on TCR
sequence details from the respective clonotypes B3, B5, and B6 (Table S1). After that,
the entire complex was aligned to an available ternary complex (PDB entry 3H9S)25.
The binding interface between complementarity determining regions (CDRs) of TCR
and theKK10 peptide was optimized globally at atomic level by a Potential Smoothing
and Search method in TINKER package37. The second template followed a similar
procedure, but with a newly released co-crystal structure (PDB entry: 4G8G) as the
input (see main text).
Molecular dynamics simulations. Each HLA B*2705-KK10-TCR complex was
solvated in a 77.5 A˚ 3 128.0 A˚ 3 76.5 A˚ water box, where the system was firstly
neutralized with counter ions, and then further ionized in a 150 mMNaCl in order to
mimic in vivo physiological environment. The solvated system was minimized by
20,000 steps, then followed by a,1 ns equilibration (with a 0.5-fs timestep) in 1 atm
and 310 K. In each system, five snapshots at the second half of the equilibration were
randomly picked as starting structures for up to 50 ns long molecular dynamics
simulations and independent 60 1 ns free energy perturbation (FEP) calculations for
each system, with an aggregate of 1.7 microseconds MD simulation time for all
clonotypes and their variants. The unbound (free) state of the FEP calculation was
modeled with the binary complex of only HLA-KK10, which was prepared with a
similar protocol employed for the bound system of HLA B*2705-KK10-TCR
complex. The particle-mesh Ewald (PME) method was used for the long-range
electrostatic interactions38, while the van der Waals interactions were handled with
usual smooth cutoff with a cutoff distance of 12 A˚. All molecular dynamics
simulations have been performed with a specially optimized NAMD2 molecular
modeling package for Blue Gene39,40, with a 1.5-fs timestep in NPT ensemble at
1 atom and 310 K. Molecular dynamics simulations have been widely used in
modeling biological systems to complement experiments, which can provide atomic
details that are often inaccessible in experiments due to resolution limits evenwith the
current most sophisticated experimental techniques22,41–50. The CHARMM22 force
field51 and TIP3P water model52 are used for proteins and solvents, respectively.
Figure 5 | Impact of alanine substitutions on FEP and antiviral efficacy. (A). The FEP simulation results for the predicted TCR-KK10 binding free energy
change due to L6A and R2A single mutations, and R2AL6A double mutation in viral peptide KK10. (B). The ability of KK10-specific clonotypes to
recognize KK10 WT peptide and alanine mutants was tested in the standard 4-h chromium release assay with peptide-loaded HLA-B*2705-expressing
GXR cells at an effector/target cell ratio of 151.
www.nature.com/scientificreports
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Free energy perturbation protocol. The binding affinity changes, due to antigenic
variations, between the TCR and HLA-KK10 complex were estimated by the free
energy perturbation (FEP) method16,17,53–60. We calculate the free energy changes for
the same mutation(s) in both the bound state (HLA-KK10-TCR 3-way binding
complex) and the free state (HLA-KK10 binary complex). For each mutation, at least
five independent runs starting from different initial configurations (taken from the
molecular dynamic simulations) are performed for better sampling. The simulation
time for each run is 6.0 ns, thus, at least 60 ns (6.0-ns3 5-runs3 2-states) simulation
time was generated for each mutation. Larger window sizes and longer simulation
durations have also been tested in our previous studies, and we found that the current
protocol gives us a reasonable convergence in the final binding affinities16,18. Please see
Note 3 in supporting data for more detailed description of the FEP protocol.
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